Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Theodoros P. Michelakos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4047-0926; OpenAlex author ID A5009995417. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 14

  1. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
  2. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  3. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  4. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  5. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  6. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  7. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… First author DOI 10.1245/s10434-020-09444-z↗
  8. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  9. Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status. Co-author DOI 10.1089/pancan.2019.0013↗
  10. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  11. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Co-author DOI 10.1016/j.canlet.2017.08.028↗
  12. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  13. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.16841↗
  14. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Co-author DOI 10.1158/2159-8290.cd-15-1177↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cristina Rosa Ferrone · 11 shared papers, 2016–2022 · strength 0.96
  2. Keith D. Lillemoe · 9 shared papers, 2017–2022 · strength 0.86
  3. Motaz Qadan · 8 shared papers, 2019–2022 · strength 0.83
  4. Vikram Deshpande · 8 shared papers, 2017–2024 · strength 0.76
  5. Theodore Sunki Hong · 7 shared papers, 2017–2022 · strength 0.63
  6. Jennifer Yon-Li Wo · 5 shared papers, 2019–2022 · strength 0.53
  7. Yurie Sekigami · 4 shared papers, 2021–2024 · strength 0.52
  8. Lei Cai · 5 shared papers, 2017–2024 · strength 0.46
  9. David P. Ryan · 5 shared papers, 2017–2022 · strength 0.46
  10. Carlos F. Fernandez-del Castillo · 4 shared papers, 2019–2022 · strength 0.44
  11. Andrew Louis Warshaw · 4 shared papers, 2019–2021 · strength 0.39
  12. Soldano Ferrone · 4 shared papers, 2017–2024 · strength 0.39
  13. David Tsai Ting · 3 shared papers, 2021–2024 · strength 0.37
  14. Carlos Fernández-del Castillo · 4 shared papers, 2017–2021 · strength 0.36
  15. Xinhui Wang · 3 shared papers, 2017–2024 · strength 0.29
  16. Nabeel M. Bardeesy · 2 shared papers, 2020–2024 · strength 0.25
  17. Avinash R. Kambadakone · 2 shared papers, 2022 · strength 0.25
  18. Jon Michael Harrison · 2 shared papers, 2021–2022 · strength 0.24
  19. Onofrio A. Catalano · 2 shared papers, 2021 · strength 0.22
  20. Colin D. Weekes · 2 shared papers, 2021 · strength 0.20
  21. Kim C. Honselmann · 2 shared papers, 2019–2022 · strength 0.19
  22. Aparna R. Parikh · 2 shared papers, 2019–2021 · strength 0.18
  23. Cristina R. Ferrone · 1 shared paper, 2024 · strength 0.17
  24. Paul A. Moore · 1 shared paper, 2024 · strength 0.17
  25. Marco Ventin · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.